Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy

Trial Profile

Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paxalisib (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 13 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 17 Jun 2022 According to a Kazia Therapeutics media release, final data from this study is expected to be submitted for publication by the end of CY2022.
  • 22 Mar 2022 Planned End Date changed from 1 Jun 2024 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top